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Standard and targeted cancer therapies for late-stage cancer patients almost universally fail due to tumor
heterogeneity/plasticity and intrinsic or acquired drug resistance. We used the telomerase substrate nucleoside
precursor, 6-thio-2′-deoxyguanosine (6-thio-dG), to target telomerase-expressing non–small cell lung cancer cells
resistant to EGFR-inhibitors and commonly used chemotherapy combinations. Colony formation assays, human
xenografts as well as syngeneic and genetically engineered immune competent mouse models of lung cancer
were used to test the effect of 6-thio-dG on targeted therapy– and chemotherapy-resistant lung cancer human
cells and mouse models. We observed that erlotinib-, paclitaxel/carboplatin-, and gemcitabine/cisplatin-resistant
cells were highly sensitive to 6-thio-dG in cell culture and in mouse models. 6-thio-dG, with a known mechanism of
action, is a potential novel therapeutic approach to prolong disease control of therapy-resistant lung cancer
patients with minimal toxicities.
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ung cancer is the most common cause of cancer-related deaths [1].
owever, tumor acquired drug resistance is one of the major reasons
hy chemotherapy and targeted therapies fail to provide durable
sponses [2, 3]. Almost universally, tumors develop resistance due to
tratumor heterogeneity and/or different mechanisms such as target
ne alterations (i.e., amplification of epidermal growth factor
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Neoplasia Vol. 20, No. 8, 2018 6-thio-dG Overcomes Chemotherapy Resistance Mender et al. 827ceptor [EGFR] and EGFR T790M mutation), downstream bypass
gnaling pathway activation (i.e., MET amplification or BRAF
utations), and phenotypic alterations (epithelial to mesenchymal
ansition), thus limiting the success of targeted therapies in lung
ncer [4,5]. Osimertinib (AZD9291) is an FDA-approved EGFR
hibitor which is used to overcome drug resistance in non–small cell
ng cancer (NSCLC) with the EGFR T790M mutation. Despite the
pressive results of this drug, acquired resistance still develops, and
tle is known about drug resistance mechanisms [6]. In addition,
ere are diverse erlotinib resistance mechanisms that can emerge in
hat is termed “persister” derived resistant clones that arise from a
ngle cell [7], indicating the complexity of resistance mechanisms.
ikewise, while subsets of lung cancer patients have durable responses
checkpoint inhibitors, in the majority of cases, resistance also
velops [8]. Thus, for all types of lung cancer systemic treatment
odalities, there remains an outstanding need to develop new
proaches to treat resistant tumors including biomarkers predictive
gnatures of response to any new treatment modalities to prolong
sease control.
Telomerase is an almost universal biomarker in advanced human
ncers [9,10]. Telomerase inhibitors are a potentially important class
targeted therapies; however, long-duration treatments result in
matological toxicities that prevent their advancement in clinical
e. For example, a lead telomerase oligonucleotide, imetelstat (IMT),
s not progressed well in clinical trials due to a long lag period to
serve clinical benefit and drug-related hematological toxicities
1,12]. When IMT therapy is temporarily stopped, tumor
lomerase is immediately reactivated and tumor telomeres rapidly
grow [13]. Thus, finding alternative strategies to target telomerase
sitive cancer cells is an urgent need.
6-thio-2′-deoxyguanosine (6-thio-dG), a modified nucleoside, is
referentially incorporated into telomeres but only in
lomerase-positive cells [14]. When an altered nucleotide,
thio-dG, is incorporated into the telomere sequence, it leads to
pid telomere uncapping, genomic instability, and cell death.
herefore, while 6-thio-dG rapidly kills the telomerase-positive
ncer cells, it has minimal effects on telomerase-negative normal
lls. Additionally, we found that 6-thio-dG induced no significant
xicity in mice (no weight loss; no changes in hematological, renal, or
er functions) [14,15]. This led us in the current study to test the
fect of 6-thio-dG on lung cancers that are resistant to platin-doublet
emotherapy or EGFR tyrosine kinase inhibitor–targeted therapies.
e find that cells resistant to first-line standard chemotherapies or
GFR-targeted therapies remain sensitive to 6-thio-dG treatment at
armacological doses. Together, our observations suggest that
thio-dG may be an effective therapeutic approach to prolong
sease control in therapy-resistant tumors.O
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ell Lines
The NCI and HCC lung cancer lines used were obtained from the
T Southwestern Hamon Center repository. Except when noted,
SCLC cell lines were grown in a Medium X (DMEM:199, 4:1,
yclone, Logan, UT) supplemented with 10% cosmic calf serum
yclone, Logan, UT) without antibiotics and incubated in a
midified atmosphere with 5% CO2 at 37°C. NSCLC cell lines
ere authenticated using the Power-Plex 1.2 kit (Promega, Madison,I) and confirmed to match the DNA fingerprint library
aintained by ATCC and confirmed to be free of mycoplasma by
Myco kit (Boca Scientific, Boca Raton, FL). Human bronchial
ithelial cells (HBECs) were cultured in bronchial epithelial growth
edium (Lonza, Allendale, NJ) with an antibiotic solution
enicillin G–streptomycin–amphotericin B) and incubated in low
ygen (2%-3%) at 37°C. PC9-derived erlotinib-sensitive (PC9-1)
d erlotinib-resistant clones [persister-derived erlotinib-resistant
one (PERC)9, PERC10, PERC13, PERC16, PC9-ER] were
nerated as previously described [7]. These cells were grown in
PMI-1640 (Sigma, St Louis, MO) supplemented with 5% fetal
vine serum (Hyclone, Logan, UT) without antibiotics. H1299
rental cells were treated long term with increasing doses of
clitaxel+carboplatin combination (2:3 ratio) to generate H1299
clitaxel/carboplatin-resistant cells. Surviving cells were cultured in
ug-free media until they repopulated the plate (one cycle); then a
cond treatment cycle was started. After 18 repetitive cycles of
eatment, H1299 T18 paclitaxel/carboplatin-resistant cells were
nerated [16].
rug Preparation
For in vitro studies, 6-thio-dG (Metkinen Oy, Kuopio, Finland) was
ssolved in DMSO/water (1:1) to prepare 10 mM stock solutions,
hich were kept frozen at −20°C. A 1 mM, final concentration stock
as prepared for in vitro experiments and added in fresh medium at
fferent concentrations. Erlotinib HCl (Selleckchem, Houston,
X) was dissolved in DMSO to prepare 10 mM stock solutions,
hich were kept frozen at −80°C. A 2.5 μM erlotinib final
ncentration was used for in vitro experiments. Osimertinib and
clitaxel (Selleckchem) were dissolved in DMSO, and carboplatin
elleckchem) was dissolved in water to prepare 10 mM stock
lutions, which were kept frozen at −80°C. A 1 mM final
ncentration stock was prepared for in vitro experiments and
ded in fresh medium at different concentrations.
For mouse in vivo studies, 6-thio-dG was prepared in 5% DMSO
r intraperitoneal (i.p.) injection or 0.4% (hydroxypropyl)methyl
llulose (Sigma, Saint Louis, MO) for oral gavage. Erlotinib was
epared in 15% Captisol (β-cyclodextrin, sulfobutyl ethers, sodium
lts) (Cydex Pharmaceuticals, Lawrence, KS) for oral gavage.
emcitabine HCl and cisplatin (Selleckchem) were dissolved in
9% NaCl saline solution for i.p. injections.
ell Viability Assay
For IC50 determinations, a panel of NSCLC cell lines was screened
ith 6-thio-dG with a four-fold dilution series in 8 different points in
-well plates. Cells were plated 24 hours prior to addition of drug,
cubated for 4 days, and assayed using MTS (CellTiter 96 Aqueous
ne Solution Cell Proliferation Assay) according to the manufac-
rer's instructions (Promega). Cell number per well ranged from
0 to 4000 cells per well inversely proportional to doubling times
ypically 2000/well). Dose-response curves were generated and IC50
lculated using in-house software DIVISA. All samples were
alyzed in triplicate, and standard deviations are from two to
ree independent experiments.
For determination of viable cells with cell counting, normal HBEC
lls (10,000 cells/cm2) were treated with 6-thio-dG (1, 3, 10 μM)
ery 3 days for 2 weeks. The cells were counted at the end of first
eek and replated for a second week. H1299 parental (800 cells/cm2)
d T18 (1600 cells/cm2) cells were grown in a Medium X (DMEM:
19
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828 6-thio-dG Overcomes Chemotherapy Resistance Mender et al. Neoplasia Vol. 20, No. 8, 20189, 4:1, Hyclone, Logan, UT) supplemented with 10% cosmic calf
rum (Hyclone) without antibiotics and treated with 6-thio-dG
, 3, 10 μM) every 3 days for 1 week.
For combination treatment of IMT and 6-thio-dG, H2087 cells
750-5000 cells/cm2) were seeded into six-well plates. After cell
tachment (next day), 5 μM IMT was added in fresh medium
retreated). Three days later, either 5 μM IMT or 1 μM 6-thio-dG
combination of IMT (5 μM) and 6-thio-dG (1 μM) was added in
esh medium and cultured for 3 days.
olony Formation Assay
PC9-1 and PERCs (PERC9, PERC10, PERC13, PERC16, and
C9-ER) were seeded in three different concentrations on six-well
ates (250-4000 cells/ well) in erlotinib or erlotinib-free medium and
eated with various drug concentrations every 3-4 days. KLN205, a
ouse lung squamous cancer cell line obtained from the American
ype Culture Collection (CRL-1453) [17], was seeded in three
fferent concentrations in six-well plates (1000-4000 cells/well) and
eated with various drug concentrations every 3-4 days. H1299
rental and T18 cells were seeded in three different concentrations
six-well plates (400-1000 cells/well) and treated with various drug
ncentrations every 3-4 days. Following 11-13 days of treatment,
lls were fixed and stained with 6% glutaraldehyde (Fisher Scientific,
ittsburgh, PA) plus 0.5% crystal violet (Sigma) solution. After
ashing with tap water, cells were air-dried and images were captured
ing a G-BOX (Syngene, model: G-BOX F3).
roplet Digital TRAP Assay (Telomerase Activity)
Quantitation of telomerase enzyme activity was performed as
scribed in [18].
elomere Dysfunction-Induced Foci (TIF) Assay
The TIF assay is based on the colocalization detection of DNA
mage by an antibody against DNA damage response factors such as
mma-H2AX, 53BP1, and telomeres using FAM-conjugated
lomere sequence (C-rich)–specific peptide nucleic acid (PNA)
obe. Briefly, cells were seeded into four-well chamber slides, and
ter the cells attached (next day), slides were rinsed twice with
osphate-buffered saline (PBS) and fixed in 4% formaldehyde
hermoScientific, IL) in PBS for 10 minutes. Then, cells were
ashed twice with PBS and permeabilized in 0.5% Triton X-100 in
BS for 10 minutes. Following permeabilization, cells were washed
ree times with PBS. Cells were blocked with 10% goat serum in
1% PBST (TritonX-100) for 1 hour. Gamma-H2AX (mouse)
illipore, Billerica, MA) was diluted 1:1000 in blocking solution
d incubated on cells for 2 hours. Following three washes with
BST (1× PBS in 0.1% Triton) and three washes with PBS, cells were
cubated with Alexaflour 568–conjugated goat anti-mouse (1:500)
nvitrogen, Grand Island, NY) for 40 minutes and then washed five
mes with 0.1%PBST.Cells were fixed in 4% formaldehyde in PBS for
minutes at room temperature. The slides were sequentially
hydrated with 70%, 90%, and 100% ethanol followed by
naturation with hybridization buffer containing FAM-conjugated
lomere sequence (C-rich)–specific PNA probe (PNA Bio, Thousand
aks, CA), 70% formamide, 30% 2× SSC, 10% (w/v) MgCl2.6H2O
isher Sci), and 0.25% (w/v) blocking reagent for nucleic acid
bridization and detection (Roche) for 7 minutes at 80°C on a heat
ock, followed by overnight incubation at room temperature. Slides
ere washed sequentially with 70% formamide (Ambion, Lifeechnologies, Grand Island, NY)/0.6× SSC (Invitrogen) (2 ×
hour), 2× SSC (1 × 15 minutes), and PBS (1 × 5 minutes);
quentially dehydrated with 70%, 90%, and 100% ethanol; and then
ounted with Vectashield mounting medium with DAPI (Vector
aboratories, Burlingame, CA). Images were captured with a
eltavision wide-field microscope using the 60× objective. TIFs were
antified as previously described [19].
stablishment of Xenograft Models
Animal experiments were approved (APN 2016-101375) by the
niversity of Texas Southwestern Institutional Animal Care and
se Committee and conducted as per institutional guidelines. A
bcutaneous xenograft mouse model of the human PC9-1 and
ERC16 NSCLC cell lines was used to evaluate the effects of
lotinib and 6-thio-dG treatment in vivo. Athymic NCR nu/nu
male mice (~6 weeks old) were used (Charles River, Wilmington,
A). A total of 2 × 106 PC9-1 and 4 × 106 PERC16 cells were
oculated subcutaneously into the left and right dorsal flanks of
ude mice in 100 μl PBS. When tumors became visible, mice were
vided into control, 6-thio-dG, and erlotinib treatment groups. In
e PC9-1 group, control mice were intraperitoneally injected with
DMSO/PBS mixture, while in the experimental group, animals
ere injected with 6-thio-dG (5 mg/kg, i.p.) or given erlotinib
5 mg/kg, oral gavage) every day for 15 days in 100 μl drug
lution per mouse. In the PERC16 group, control mice were
traperitoneally injected DMSO/PBS mixture for 12 days and
en given 0.4% (hydroxypropyl)methyl cellulose as oral gavage for
week. In the PERC16 experimental group, animals were injected
ith 6-thio-dG (5 mg/kg, i.p.). Another group was given erlotinib
5 mg/kg, oral gavage) every day for 12 days and then switched to
thio-dG (5 mg/kg, oral gavage) for 1 week in 100 μl drug
lution per mouse.
A subcutaneous xenograft mouse model was used to evaluate the
fects of 6-thio-dG treatment on paclitaxel/carboplatin-resistant
1299 T18 NSCLC in vivo. Athymic NCR nu/nu female mice
6 weeks old) were used (Charles River). A total of 3 × 106 H1299
18 cells were inoculated subcutaneously into the left and right dorsal
nks of the nude mice in 100 μl PBS. When tumors became visible
50mm3), mice were divided into control (DMSO/PBS, i.p., daily)
d 6-thio-dG treatment groups (5 mg/kg, i.p., daily).
A syngeneic tumor mouse model was used to evaluate the effects of
mbination therapy of 6-thio-dG in vivo. DBA/2 female mice
6-8 weeks old) were used (Charles River). A total of 3.6 × 105
LN205 cells were inoculated subcutaneously into the left and right
rsal flanks of the DBA/2 mice in 100 μl PBS. When tumors became
sible, mice were divided into control, 6-thio-dG, gemcitabine +
splatin, and gemcitabine + cisplatin + 6-thio-dG treatment groups.
he following concentrations were used for 6-thio-dG, gemcitabine,
d cisplatin: 2.5 mg/kg (oral gavage, daily), 15 mg/kg (i.p., every
3 days), and 1 mg/kg (i.p., every 5-6 days), respectively. The group
at was given gemcitabine + cisplatin doublet therapy for 13 days was
itched to 6-thio-dG alone (5 mg/kg, i.p.) for 2-4 days at the end of
eatment in 100 μl drug solution per mouse. Animals were weighed
ery other day during the treatment period. Tumor volumes were
easured by calipers and recorded every 2 days. Tumor volumes were
lculated by taking the length to be the longest diameter across the
mor and width to be the corresponding perpendicular diameter using
e following formula: (length × width2) × 0.5. The animals were
crificed by CO2 inhalation 24 hours after the last dose of treatment.
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Figure 1. (A) Column scatter graph shows the IC50 values of NSCLC cells on log10 scale following 6-thio-dG treatment. (B) Lack of
correlation between initial telomere length and 6-thio-dG IC50 values of NSCLC lines (R
2: 0.03878, P = .2056). (C) ddTRAP assay confirms
telomerase inhibition upon IMT treatment in H2087 NSCLCs but no inhibition upon 6-thio-dG treatment. Cells treated with vehicle or
6-thio-dG (1 μM, 3 days) or IMT (5 μM, 6 days) or combination of IMT and 6-thio-dG (pretreated with 5 μM IMT 6 days and then 6-thio-dG
3 days). Negative control: DEPC water (SDs from three independent experiments, control versus 6-thio-dG: P = ns, two-tailed unpaired t
test). (D) The cell counts of H2087NSCLCs treatedwith either vehicle or 6-thio-dG (1 μM, 3 days) or IMT (5 μM, 6 days) or combination of IMT
and 6-thio-dG (pretreated with 5 μM IMT and then 6-thio-dG 3 days) (n = 7-9, pooled from three independent experiments, two-tailed
unpaired t test, ***P = .0005, ****P b .0001). (E) TIF assay confirms induction of TIFs with 6-thio-dG treatment (1 μM, 3 days) and the
reduction of TIFs when the cells were pretreated with IMT (5 μM). TIF N 5: cells that have more than 5 TIFs in the nucleus. n = 95 (control).
n = 95 (6-thio-dG), n = 57 (IMT), n = 70 (6-thio-dG + IMT). Two-tailed unpaired t test, control versus 6-thio-dG: ****P b .0001, control
versus IMT: ns, 6-thio-dG versus 6-thio-dG + IMT: *P = .0105, IMT versus 6-thio-dG + IMT: ns. Supplemental data associated with this
figure can be found in Supplemental Fig. S1.
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This mouse tumor model with an activated oncogenic allele of K-ras
s been previously described [20]. The mice were inbred onto 129S2A
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00 days old and continued every day for 14 days (i.p.). The animals
ere sacrificed by CO2 inhalation 24 hours after the last dose of
eatment. Formalin-fixed, paraffin-embedded tissue was sectioned
μm thick), deparaffinized, and stained with hematoxylin I and eosin
(Fisher Scientific). Surface area (R2) of neoplastic lesions was
easured by using Nanozoomer digital pathology software. Neoplastic
sions were accepted as spheres. Tumor volumes were calculated by
ing the following formula: 4/3·π·R3. Three sections were used for
ch sample, and each section was 25 μm apart from each other.
elomere Shortest Length Assay (TeSLA)
The TeSLA was performed as described in [21] to measure the
erage and the shortest telomere lengths.
atistical Analysis
Unless otherwise indicated, all data are presented as mean values ±
andard deviation (SD) for at two to three replicates. KLN205 tumor
lumes in each group were normalized to day 1 measurement in its
n group, and therefore, graphs are shown as percentages.
gnificant differences between experimental conditions were deter-
ined using two-tailed, unpaired Student's t test (*P b .05,
P b .005, ***P b .0005, ****P b .0001, ns: P N .05). ANOVA
ixed-effect models were used to determine the differences between
ntrol and treatment groups for the time-dependent in vivo
periments (tumor growth data) by using R version 3.4.1 and the
me package. Graphs and other statistical analysis were done using
raphPad Prism software version 7.re
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elomerase Dependency on Cell Killing Effects of 6-thio-dG for
SCLC and HBECs
In our previous study, we showed that 6-thio-dG induces apoptosis
telomerase-positive HeLa cervical cancer, pediatric brain tumor
B004, CCHMC-DIPG1), and melanoma cell lines (A375 and
OX-IMVI BR) [22,23]. In this study, we determined the drug
sponse phenotypes across a panel (n = 43) of NSCLC lines
presenting a wide variety of lung cancer oncogenotypes; response
enotypes to clinically available drugs; and NSCLCs derived from
rrent, former, and lifetime never smokers. We tested these 43
fferent NSCLC lines in 96-well plates and assayed with 8 different
ncentrations of 6-thio-dG over a 4-day period to determine IC50
lues. We found a range of 6-thio-dG IC50 values with a largegure 2. (A) Colony formation assay of erlotinib-sensitive (PC9-1) and (B) -
indicated doses for 11-13 days. (C) Colony formation assay of PERC9 er
thio-dG at indicated doses for 11-13 days. Cells were then fixed and
ological replicates was shown for each experimental sample. (D) Resu
ght TeSLA PCRs (30 pg of each reaction) were performed for each
termine the average telomere length (AvgTL, kb), shortest 20% (kb), and
al gavage of 6-thio-dG in PC9-1– and PERC16-derived xenografts. A tota
ily given to the PC9-1–derived mice for 15 days. A total of 15 mg/kg erlo
RC16-derived mice for 12 days. Following 12 days of erlotinib treatme
ally every day for 1 week. Data in these figures were presented as me
lotinib: P b .0001, erlotinib versus 6-thio-dG: P = .01, control versus 6-
lotinib versus 6-thio-dG: P b .0001, control versus 6-thio-dG: P b .0001
vage:P = .00017 in Figure 2F;ANOVAmixed-effectmodels.). Supplem
gs. S2 and S3.oportion having IC50 values in the nanomolar to low micromolar
ncentration (Figure 1A and Supplementary Fig. S1A). The IC50
lues for 6-thio-dG in the NSCLC lines as expected were
dependent of their initial telomere length (Figure 1B). In order to
st if the cell killing effects were telomerase dependent, we selected
thio-dG–sensitive cell line H2087 and pretreated cells with the
lomerase inhibitor IMT, and then continued drug treatment with a
mbination of IMT and 6-thio-dG to see if the cells would be
scued from 6-thio-dG toxicity (Figure 1, C and D). While IMT
eatment (5 μM, 3 days) almost completely inhibited telomerase
tivity with minimal effect on cell growth, 6-thio-dG (1 μM, 3 days)
d not inhibit telomerase activity in H2087 cells (Figure 1C) but had
substantial and quick effect on cell viability (Figure 1D). We
served that while 1 μM 6-thio-dG killed ~45% of the cells in
days, short-term treatment with IMT did not affect cell growth
tes. However, pretreatment with IMT partially rescued the
ll-killing effect of 3 days of 6-thio-dG treatment. However, a
bset (~22%) of the cells was still sensitive to 6-thio-dG even in the
esence of IMT (Figure 1D).
One explanation is that even the very low residual telomerase activity in
e cells after IMT treatment leads to some 6-thio-dG incorporation into
lomeres in a subset of cells. To determine if this explanation was correct,
e determined the presence of TIF under these conditions and found that
thio-dG induces TIFs (32% of cells treated with 6-thio-dG alone have
ore than 5 TIFs in the nucleus after 72 hours) correlating with
ll-killing effect, while inhibition of telomerase with IMT reduced the
currence of TIFs (14% of the cells treated with 6-thio-dG after IMT
eatment that have more than 5 TIFs in the nucleus) (Figure 1E) and
scued most of the cells from 6-thio-dG–induced cell death. This
ggests that TIFs may trigger 6-thio-dG–induced cell death (Figure 1,
-E). We used primary cultures of HBECs that are telomerase silent to
st the toxicity of 6-thio-dG on telomerase-negative cells and observed
inimal cell growth inhibition effects with treatment over a 2-week
riod (supplementary Fig. S1, B and C). Our previous studies also
owed that human normal fibroblasts, colonic epithelial cells, skin
ratinocytes, skinmelanocytes, and skin fibroblasts are not as sensitive to
thio-dG as telomerase-positive cancer cells and 6-thio-dG causes G2/M
rest in telomerase-positive cells with negligible effect in telomerase-ne-
tive cells [14,22,23]. These results are consistent with the proposed
echanism of action of 6-thio-dG indicating that expression of
lomerase in cells increases the sensitivity to 6-thio-dG with minimal
fect on normal cells. In addition, it is possible that genomic damage
served in normal cells may lead to a senescence-like state that may be
versible.resistant (PERC16) cells thatwere treatedwith erlotinib or 6-thio-dG
lotinib-resistant cells thatwere treatedwith erlotinib, osimertinib, or
stained with crystal violet. Representative image of three to five
lts of TeSLA using DNA for PC9-1, PERC9, PERC13, and PERC16.
DNA sample. TeSLA image quantification software was used to
b1.6 kb (%).P .01, fold change 2. (E-F) Intraperitoneal injectionor
l of 15 mg/kg erlotinib (oral gavage) or 5 mg/kg 6-thio-dG (i.p.) was
tinib (oral gavage) or 5 mg/kg 6-thio-dG (i.p.) was daily given to the
nt, 5 mg/kg 6-thio-dG treatment alone was continued to be given
an values ± standard error of the mean (n = 3-6) (control versus
thio-dG: P = .000 in Figure 2E; control versus erlotinib: P = .043,
, comparison for days 12-20 between control versus 6-thio-dG oral
ental data associatedwith this figure canbe found in Supplemental
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It has been shown that EGFR mutant PC9 NSCLCs are sensitive
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RCs [7].
In this study, we tested a subset of these erlotinib-resistant clones
determine if they were also resistant to 6-thio-dG. We seeded
ERCs (PERC9, PERC10, PERC13, PERC16, and PC9-ER) into
x-well plates cultured in erlotinib-containing medium. Previous-
, it was demonstrated that the resistance of PERC10, PERC13,
d PERC16 to erlotinib was related to an increased ERK-pathway
pendence. However, the resistance of PERC9 was linked to
790M-EGFR mutation, while PC9-ER is a polyclonal erlotini-
resistant cell line. We found that erlotinib-sensitive (PC9-1) and
esistant (PERC9, PERC10, PERC13, PERC16, and PC9-ER)
ones all remained very sensitive (in the low nanomolar range) to
thio-dG irrespective of the mechanism of erlotinib acquired
sistance (Figure 2, A-B and Supplementary Fig. S2, A-E).
dditionally, we cultured PERC16 in erlotinib-free medium to
mpare with erlotinib-containing medium conditions and found
at PERC16 clones were still sensitive to 6-thio-dG (30 nM) (data
t shown). In another experiment, we tested a third-generation
GFR inhibitor osimertinib (selective for both TKI sensitizing and
790M resistance mutations) in PC9-1 and PERC9 clones to
termine if erlotinib-sensitive PC9-1 and erlotinib-resistant
ERC9 clones that harbor T790M mutation were sensitive to a
xt-generation EGFR inhibitor. We found that while the PC9-1
lotinib-sensitive cells were also sensitive to 10 nM osimertinib
upplementary Fig. S3A), the PERC9 erlotinib-resistant cells were
sistant to 10-100 nM osimertinib (Figure 2C). Despite this
sistance to erlotinib and osimertinib, PERC9 cells remained
ghly sensitive to 30 nM 6-thio-dG (Figure 2C). However, the
sults with 10, 30, and 100 nM osimertinib looked similar in
C9-1 cells, showing the non–dose-dependent effect of osimertinib
these cells. There are two possible explanations for the non–
se-dependent manner. The first explanation is that cells are not
logarithmic decline phase in between 10 nM and 100 nM
ncentration of osimertinib; they are in plateau phase. The second
planation is the presence of osimertinib resistance colonies in
all subpopulation. Resistance can emerge from this small
bpopulation, but it may require culturing these cells long term.
addition, we investigated the relationship between telomere
ngth and sensitivity to 6-thio-dG, even though we previously found
lack of correlation between telomere length and 6-thio-dG
nsitivity [14]. We performed the TeSLA to quantitate the average
d shortest telomeres in the cells targeted with 6-thio-dG. We
und that the average telomere length of PERC9, PERC13, and
ERC16 erlotinib-resistant clones was longer and the percentage of
e cells with telomeres shorter than 1.6 kb was less than the PC9-1
lotinib-sensitive clone (Figure 2D). These results indicate that
thio-dG targets cells with both short and long telomeres equally,
monstrating that the cell-killing effect is independent of the initialgure 3. (A) Colony formation assay of H1299 parental and paclitax
epresentative image of three biological replicates is shown for each
1299 T18 cells treated with 3 and 10 μM6-thio-dG for 1 week (control;
) Results of TeSLA using DNA for H1299 parental and H1299 T18. Eig
NA sample. TeSLA image quantification software was used to determ
d b1.6 kb (%). P b .01, fold change N2. (D) Intraperitoneal injection o
days. Control versus 6-thio-dG: P b .0001.lomere length of the tumor cell as also demonstrated in the large
SCLC panel tested (Figure 1B).
In order to assess anticancer activity of 6-thio-dG in vivo, we used the
lotinib-sensitive (PC9-1) and -resistant (PERC16) clones to establish
nografts in nude mice. Based on our previous in vivo dose-defining
sults [14], 5 mg/kg of 6-thio-dG (i.p. and/or oral gavage) or 15mg/kg
lotinib (oral gavage) was given daily. As expected, the PC9-1–derived
oup remained sensitive to erlotinib, whereas tumors continued to
ow with erlotinib treatment in the erlotinib-resistant PERC16-der-
ed group compared to control treatment groups (Figure 2, E and F).
fter 12 days of erlotinib treatment of PERC16 tumors, we provided
thio-dG (via oral gavage daily at 5 mg/kg) for an additional 1 week.
his resulted in ~35% tumor shrinkage (Figure 2F). Thus, the resistant
mor growing in the presence of 15mg/kg erlotinib remained sensitive
6-thio-dG in vivo, demonstrating that 6-thio-dG results in
ug-resistant tumor shrinkage.
To test the ability of 6-thio-dG to overcome chemotherapy
sistance more broadly, we used H1299 NSCLC cells resistant to
clitaxel/carboplatin doublet therapy. The H1299 parental cells are
nsitive to 100 nM paclitaxel combined with 150 nM carboplatin.
hese sensitive cells were treated with paclitaxel/carboplatin doublet
erapy in clinically relevant doses for 8-9 months for 18 cycles (1
cle: a drug on–drug off period) to develop resistant cell lines, as
eviously described [16]. The cells, termed H1299 T18, acquired a
-fold increased resistance to paclitaxel/carboplatin chemotherapy.
his resistance had two components: the first was the upregulation of
BC transporter expression leading to classical multidrug resistance.
he second was the upregulation of KDM lysine demethylases [16].
was this latter mechanism that resulted in these platin-taxane–
sistant NSCLC cells to become exquisitely sensitive to KDM lysine
methylase (Jumonji) inhibitors [16]. We tested the effects of
thio-dG (1, 3, and 10 μM) on these sensitive and resistant isogenic
1299 cells and found that both the H1299 T18 NSCLC resistant
ll and the parental H1299 cells remain sensitive to 6-thio-dG
igure 3, A and B). We also performed the TeSLA assay for H1299
18 paclitaxel/carboplatin-resistant cells and found that H1299
18–resistant cells have shorter average telomere length (% of cells
ith b1.6 kb telomere length was higher) compared to H1299
rental (paclitaxel/carboplatin sensitive) cells (Figure 3C). In
mmary, H1299 T18 cells that demonstrated resistance to
atin-taxane chemotherapy including both upregulation of expres-
on of both ABC transporter and selected KDM demethylases
mained sensitive to 6-thio-dG treatment.
In order to assess the anticancer activity of 6-thio-dG in vivo, we used
e paclitaxel/carboplatin (H1299 T18)–resistant cells to establish
nografts in nude mice. We observed that 6-thio-dG (5 mg/kg, i.p.,
ily) significantly reduced the tumor growth rate inH1299T18, whereas
eatment with a vehicle control did not (Figure 3D). Thus, 6-thio-dG
ay be a valuable smallmolecule drugwithminimal toxicities for reversingel:carboplatin-resistant cells at indicated doses for 11-13 days.
experimental sample. (B) The cell counts of H1299 parental and
DMSO:water) (SDs from two to three independent experiments).
ht TeSLA PCRs (30 pg of each reaction) were performed for each
ine the average telomere length (Avg TL, kb), shortest 20% (kb),
f 6-thio-dG (5 mg/kg, daily) in H1299 T18–derived xenografts for
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Figure 4. (A) Telomerase activity of KLN205 by using ddTRAP. H1993 NSCLC cell line is a positive control. (B) In vitro colony formation
assay of KLN205 mouse lung tumor cells at indicated doses for 11-13 days. Cells were then fixed and stained with crystal violet.
Representative image of three biological replicates are shown. (C) A syngeneic tumor mouse model in DBA/2 mice. 6-thio-dG: 2.5 mg/kg
(oral gavage, daily), gemcitabine (Gem): 15 mg/kg (i.p., every 2-3 days), and cisplatin (Cis): 1 mg/kg (i.p., every 5-6 days) for 13 days.
Control versus 6-thio-dG + Gem+Cis: P b .0001, control versus Gem+Cis: P b .0001. 6-thio-dG + Gem+Cis versus Gem+Cis: P b .05,
ANOVA mixed-effect models. (D) Comparison of tumor volumes between Gem+Cis and Gem+Cis+6-thio-dG at day 11. (E)
Representative tumor images (two tumors from each experimental group). (F) Percentage of total lymphocyte count shown following
vehicle, Gem+Cis, and Gem+Cis+6-thio-dG. Gem+Cis versus Gem+Cis+6-thio-dG: P = ns, two-tailed unpaired t test. (G) The
experimental group that was given Gem+Cis doublet therapy for 13 days was switched to 6-thio-dG alone (5 mg/kg, i.p.) at the end of
treatment (red line).
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Figure 5. (A) H&E staining. Vehicle (5% DMSO) or 6-thio-dG (5 mg/kg) was injected into KRASLA1 strain mice (~300 days old) for 14 days
(daily, i.p.). Harvested lungs were analyzed for the number and volume of the tumors. Two representative mouse lungs are shown. (B)
Tumor volumes (mm3) of experimental groups (vehicle or 6-thio-dG treatment). Average tumor volumes were calculated from each
H&E-stained lung section of five mice (3 sections per mouse). Each dot represents an average tumor volume of a section in mouse lung.
Control versus 6-thio-dG: P b .0001, two-tailed unpaired t test.
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rinks Tumors in an Immunocompetent Syngeneic Mouse Model
We next aimed to simulate clinical therapy with 6-thio-dG in vivo
ith combination therapy in the context of a functioning immune
stem. Since some immune cells transiently express telomerase and
uld therefore be potentially targeted by 6-thio-dG, we tested the
fects of 6-thio-dG in a syngeneic (immunocompetent) tumor
owth mouse model. Thus, we first tested 6-thio-dG in vitro on a
ouse lung squamous cancer cell line, KLN205 [17], and found that
e KLN205 telomerase-expressing cells (Figure 4A) were sensitive to
thio-dG in in vitro colony formation assays (Figure 4B). We
troduced KLN205 cells into DBA/2 mice that have a fully
mpetent immune system and are histocompatible with the
lografted KLN205 tumor cell line. After establishing
LN205-derived tumors, we tested the anticancer activity of
thio-dG (2.5 mg/kg, oral gavage, daily), gemcitabine+cisplatin
one, and gemcitabine+cisplatin in combination with 6-thio-dG. We
wered 6-thio-dG concentration from 5 mg/kg to 2.5 mg/kg in this
ug combination model and found that the percentage of tumor
lumes of control, 6-thio-dG, gemcitabine+cisplatin, and gemcita-
ne+cisplatin+6-thio-dG was ~506%, ~268% (not shown in graph),
04%, and 42% at the end of a 13-day treatment, respectively
ercentage changes compared to the tumor volume in the control
ice at a given day). Thus, while the combination of gemcitabine
d cisplatin partially inhibited progressive tumor growth, it did
t shrink the tumor. The addition of 6-thio-dG together with
e gemcitabine and cisplatin combination led to ~50% tumor
rinkage (Figure 4, C-E). Importantly, total lymphocyte counts did
t change between mouse groups during the 13-day treatmentriod (Figure 4F); however, we did observe a small weight loss in
thio-dG + Gem+Cis compared to control (this difference is
gnificant with ANOVA). Thus, combining 6-thio-dG with first-line
ng cancer therapy was effective in this mice model. Finally, to
termine if 6-thio-dG can overcome initial KLN205 gemcitabine+-
splatin resistance, on day 13, we switched treatment from
mcitabine+cisplatin which had no effect on KLN205 tumor
owth to treatment with 6-thio-dG alone (5 mg/kg, i.p), and the
end showed rapid tumor shrinkage but lacked statistically
gnificance due to inadequate tumor sample (Figure 4G). Thus, in
preclinical model of “front-line” lung cancer chemotherapy, a
ngeneic lung squamous cancer model shows dramatic responses to
e combination of 6-thio-dG and gemcitabine+cisplatin in vitro and
vivo.
thio-dG Reduces Tumor Size in a KRAS Mutant Genetically
ngineered Mouse Model (KRASLA1) of Lung Cancer
We assessed the anticancer effects of 6-thio-dG in a genetically
gineered mouse model (KRASLA1) that carries oncogenic alleles of
RAS (G12D) activated by spontaneous recombination events which
capitulate the spontaneous oncogene activation as seen in human
ncer in the presence of an intact immune system [20]. In a pilot
periment with 300-day-old mice with significant tumor burden, we
served a 66% reduction in tumor volume with 6-thio-dG
eatment (i.p., daily, 5 mg/kg, 14 days) and did not observe weight
ss between mouse groups during the treatment period (Figure 5).iscussion
hemotherapy and/or targeted therapies for advanced NSCLC often
ovide partial antitumor responses in patients but almost universally
e associated with subsequent tumor recurrences requiring additional
eatments in the second- and third-line setting. It appears that tumor
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836 6-thio-dG Overcomes Chemotherapy Resistance Mender et al. Neoplasia Vol. 20, No. 8, 2018lls remaining after primary therapy persist in a “drug-tolerant”
persister”) state for weeks to months and then move to a
rug-resistant” state [24, 25]. Due to tumor cell heterogeneity/
asticity, a single tumor cell can expand and emerge with diverse
erapy resistance mechanisms. Thus, some drug-resistant “persisters”
ill respond to additional therapy, while other “persisters” will not
]. Therefore, it is important to identify therapies that work across
sistant/persister cell phenotypes to provide patients with durable
ng-lasting remissions.
In our previous study, we described the nucleoside analogue 6-thio-dG
a potential therapeutic agent and demonstrated its mechanism of
tion. 6-thio-dG affected telomerase-positive cancer cells but had
inimal toxicity to long-term–treated mice and to telomerase-negative
rmal human colonic epithelial and fibroblast cells [14].We also showed
at targeting telomerase with 6-thio-dG overcame therapy resistance in
diatric brain tumors (demonstrating that 6-thio-dG can cross the blood
ain barrier) [24]. In addition, we demonstrated sensitivity to 6-thio-dG
BRAF and checkpoint inhibitor–resistantmelanomas [22, 23].Here in
is study, we extended our preclinical studies to more clinically relevant
ng cancer model systems. Thus, we tested the anticancer effect of
thio-dG on first-line EGFR tyrosine kinase inhibitor targeted therapy–
platin-taxane chemotherapy–resistant NSCLC cells. Although the
action of the oral administered 6-thio-dG that reaches systemic
rculation or the tumor was not investigated in this study, here for the
st time, we demonstrate the efficacy of 6-thio-dG through oral
ministration.
We used three different in vivo models to demonstrate that
thio-dG is effective in overcoming lung cancer drug resistance to
GFR targeted therapy and platin-doublet chemotherapy. Two of the
man lung cancer preclinical models (erlotinib-resistant EGFR
utant NSCLCs and paclitaxel/carboplatin-resistant NSCLCs)
owed sensitivity in xenografted tumors to 6-thio-dG delivered
ally or by i.p. injection with significant tumor shrinkage. We also
sted the effects of 6-thio-dG in a syngeneic mouse tumor model
ith intact immunity as a third in vivo model. Since some
oliferating immune cells transiently express telomerase, there was
e possibility that 6-thio-dG could have reduced T-cell–mediated
titumor effects. We used the KLN205 mouse cancer cell line in
BA/2 mice since this is a well-established model of combining
mcitabine and cisplatin's efficacy and safety [26]. When we
mbined 6-thio-dG with gemcitabine and cisplatin, we observed an
ditional ~50% reduction in tumor volume compared to gemcita-
ne and cisplatin combination therapy alone over a 13-day treatment
riod. In addition, we demonstrated that adding 6-thio-dG
eatment to a KLN205 tumor not responding to gemcitabine+cis-
atin therapy resulted in further dramatic tumor shrinkage. We saw
o correlation in NSCLCs with response to 6-thio-dG and tumor
lomere length. In addition, the KLN205 experiments showed that
thio-dG works in mouse tumors that have relatively long telomeres.
Finally, we showed that 6-thio-dG treatment resulted in significant
mor reduction in a genetically engineered mutant KRAS model of
ng adenocarcinoma again with an intact immune system. In
dition, in the xenograft and GEMM experiments, we did not
serve weight loss during the treatment, and the total lymphocyte
unt did not change by adding 6-thio-dG to the gemcitabine+cis-
atin therapy. This is consistent with our previous studies showing
ss toxicity of 6-thio-dG alone in wild-type mice up to 25 days
ack of weight loss; no changes in hematological, renal, or liver
nctions) [14].There is an urgent clinical need for effective therapeutic targets to
verse drug resistance. In the current study, we provide compelling
eclinical evidence of significant efficacy of 6-thio-dG in a variety of
SCLC clinical settings as a first-line therapy as a single agent or in
mbination with conventional therapies, or in the maintenance
tting. In summary, 6-thio-dG is a highly promising telomerase--
ediated telomere-targeted therapy for NSCLC that has activity in
treated cancers and in NSCLCs with resistance to either targeted
erapy or platin-doublet chemotherapy. These findings support the
rther investigation of candidate biomarkers, which predict
nsitivity to 6-thio-dG and could be translated into the clinic by
entifying a biomarker-defined patient population that would receive
eater benefit from 6-thio-dG.
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